Notably, the monoclonal antibodies Denosumab and Romosozumab have been developed to inhibit RANKL [231] and sclerostin, respectively [233], indicating the pivotal role of these molecular targets in osteoporosis development. This evidence concerns the gene SOST and osteoporosis.